ATIR101 + T-cell depleted HSCT from a related, haploidentical donor for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Dec 2016: Trial registered, NCT02999854
  2. 29 Nov 2017: Trial started, NCT02999854
  3. 17 Dec 2021: Trial terminated, NCT02999854
  4. 24 May 2022: Trial results posted, NCT02999854

The trials

NCT02999854: Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

State
Stopped early
Phase
Phase 3
People
63 taking part
Started
29 Nov 2017
Primary completion
9 Nov 2021
Arms
ATIR101
Results
Posted on the registry
  1. 21 Dec 2016: Trial registered
  2. 29 Nov 2017: Trial started
  3. 17 Dec 2021: Trial terminated
  4. 24 May 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.